ERBB2 and breast cancer: Following the results of the phase 3 PALOMA-2 trial, the FDA, in 2017, granted regular approval to palbociclib and expanded its use as first-line therapy in combination with an aromatase inhibitor in postmenopausal women with HR+/HER2− advanced or metastatic BC.